BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat 2019;26:1388-403. [PMID: 31392812 DOI: 10.1111/jvh.13187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Trickey A, Semchuk N, Saliuk T, Sazonova Y, Varetska O, Walker JG, Lim AG, Stone J, Vickerman P. Has resourcing of non-governmental harm-reduction organizations in Ukraine improved HIV prevention and treatment outcomes for people who inject drugs? Findings from multiple bio-behavioural surveys. J Int AIDS Soc 2020;23:e25608. [PMID: 32851812 DOI: 10.1002/jia2.25608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chaillon A, Thurairajah PH, Hsiang JC, Martin NK. What is required for achieving hepatitis C virus elimination in Singapore? J Gastroenterol Hepatol. 2021;36:1110-1117. [PMID: 32777859 DOI: 10.1111/jgh.15211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kåberg M, Weiland O. Hepatitis C elimination - Macro-elimination. Liver Int 2020;40 Suppl 1:61-6. [PMID: 32077600 DOI: 10.1111/liv.14352] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Artenie A, Luhmann N, Lim AG, Fraser H, Ward Z, Stone J, Macgregor L, Walker JG, Trickey A, Marquez LK, Abu-raddad LJ, Ayoub HH, Walsh N, Hickman M, Martin NK, Easterbrook P, Vickerman P. Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00311-3] [Reference Citation Analysis]
5 García-Herola A, Domínguez-Hernández R, Casado MÁ. Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C. PLoS One 2021;16:e0260608. [PMID: 34928962 DOI: 10.1371/journal.pone.0260608] [Reference Citation Analysis]
6 Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol 2021;6:391-400. [PMID: 33857445 DOI: 10.1016/S2468-1253(20)30365-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lim AG, Stone J, Hajarizadeh B, Byrne M, Chambers GM, Martin NK, Grebely J, Dore GJ, Lloyd AR, Vickerman P. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons. Hepatology 2021;74:2366-79. [PMID: 34105797 DOI: 10.1002/hep.32002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Moazen B, Stöver H, Dolan K, Jahn A, Neuhann F. Prisoners should not be left behind in HCV research and policies. Harm Reduct J 2020;17:33. [PMID: 32448290 DOI: 10.1186/s12954-020-00379-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]